Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET

Company Participants

John Menditto - VP, IR and Corporate Communications

Dave Mazzo - CEO

David Slack - President and Chief Business Officer

James Nisco - VP, Finance and Treasury

Kristen Buck - EVP, Research and Development and Chief Medical Officer

Conference Call Participants

Peter Enderlin - MAZ Partners

Shubhendu Roy - Brooklyn Capital Markets

Operator

Welcome to the Lisata Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, November 10, 2022.

I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Lisata. Please go ahead, sir.

John Menditto

Thank you, operator, and good afternoon, everyone. Welcome to Lisata's Third Quarter 2022 Conference Call to discuss our financial results and provide a business update.

Joining me today from our management team are Dr. David Mazzo, Chief Executive Officer; David Slack, President and Chief Business Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Vice President of Finance and Treasury.

Shortly before this call, we issued a press release announcing our third quarter 2022 financial results, which is available under the Investors and News section of the company's website, along with the webcast replay of this call.

If you've not received the news release or if you'd like to be added to the company's e-mail distribution list, please e-mail me at jmenditto@lisata.com.

Before we begin, I remind you that comments made by management during this conference call contain forward-looking statements that involve risks and uncertainties regarding the future operations and results of Lisata. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-Q, 8-K and 10-K which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, Thursday, November 10, 2022.

Lisata undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.

With that, I will now turn the call over to Dr. Mazzo. Dave?

Dave Mazzo

Thank you, John, and good afternoon, everyone. It gives me great pleasure today to host this, our first quarterly conference call at Lisata Therapeutics, where we will provide an overview of recent business highlights and discuss our third quarter 2022 financial results.